-
Media Release
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
-
Media Release
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
-
Media Release
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
-
Story
Novartis in San Diego: A Quarter Century of R&D Innovation -
Story
Designing for the Future: The Next Era of Biomedical Research in San Diego